Question

Write an analysis describing how the selected medication class relates to the selected systems disorder. (Medication: Meropenem and system disorder: Meningitis)

• 300 words minimum.

• A strong connection and correlation are made between the selected medication and disease process.

Answer 1

Antimicrobial resistance in Streptococcus pneumoniae has become a serious concern throughout the world .The prevalence of pneumococcal resistance was reported to be high in some Asian countries, western Europe, South Africa and the southern part of the United States . According to the increasing prevalence of in vitro pneumococcal resistance, therapeutic options for pneumococcal infections have been changed. Pneumococcus is the most common cause of acute bacterial meningitis in adults, and the mortality rate of pneumococcal meningitis is as high as about 25-30% . For pneumococcal meningitis, treatment failure of a single-drug regimen such as penicillin, chloramphenicol, third-generation cephalosporins, and vancomycin has been frequently reported . The combination regimen of ceftriaxone and vancomycin or ceftriaxone plus rifampin is recommended for empirical treatment of pneumococcal meningitis, especially in countries with a high prevalence of resistance (

Meropenem, which has an excellent anti-pneumococcal activity and less potential for seizure, could be one of the candidate regimens for pneumococcal meningitis (15). However, there have been only a few studies on the therapeutic efficacy of meropenem or a meropenem-based regimen in the treatment of penicillin-resistant pneumococcal meningitis (16-19). We have herein evaluated the therapeutic efficacy of meropenem monotherapy and the combination of meropenem plus vancomycin for meningitis using a rabbit model of meningitis caused by penicillin-resistant S. pneumoniae (PRSP).

broad spectrum antibiotic Merrem (meropenem) appears to be a safe and effective treatment for bacterial meningitis.according to the study there are several trips are going upon them.

In a trial involving 190 children with bacterial meningitis, the drug was as effective as the third-generation cephalosporin, cefotaxime (Roussel's Claforan), which is the current treatment of choice for the disease,

At a dosage of 120mg/kg/day, meropenem eradicated all of the causative pathogens, which included Hemophilus influenza, Neisseria meningtidis and Streptococcus pneumonia. Cefotaxime at a dosage of 225mg-300mg/kg/day was as effective as meropenem but failed to eradicate Staphylococcus aureus in one patient, . There was one death in the meropenem group and two in the cefotaxime group.

Side effects were generally mild in both treatment groups, and included a low incidence of nausea and diarrhea. Seizures occurred in six patients receiving meropenem and in three receiving cefotaxime. Among those having seizures in the meropenem group, two had seizures previous to therapy and two had neurological abnormalities which could have contributed to their seizures, The drug should become useful with the emergence of cephalosporin resistant pneumococcal strains, he added.